1hon MSN
Is Editas Medicine Going to $0?
The biotech could run out of funding before it can launch a single product.
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal CarePartnership ...
Early clinical data indicates the treatment leads to dose-dependent increases in functional AAT protein, which is altered in the condition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results